Femtrace is a drug owned by Allergan Pharmaceuticals International Ltd. It is protected by 3 US drug patents filed in 2013. Out of these, 1 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 02, 2025. Details of Femtrace's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7572779 | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
Oct, 2025
(10 months from now) | Active |
| US7799771 | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
Dec, 2021
(2 years ago) |
Expired
|
| US6962908 | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
Dec, 2021
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Femtrace's patents.
Latest Legal Activities on Femtrace's Patents
Given below is the list of recent legal activities going on the following patents of Femtrace.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 24 Oct, 2022 | US7799771 |
| Maintenance Fee Reminder Mailed Critical | 10 May, 2022 | US7799771 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Feb, 2021 | US7572779 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Mar, 2018 | US7799771 |
| Post Issue Communication - Certificate of Correction | 24 Jan, 2018 | US7799771 |
| Post Issue Communication - Certificate of Correction | 24 Jan, 2011 | US7572779 |
| Application Is Considered for C of C | 30 Nov, 2010 | US7572779 |
| Mail-Petition Decision - Dismissed Critical | 02 Nov, 2010 | US7572779 |
| Petition Decision - Dismissed Critical | 02 Nov, 2010 | US7572779 |
| Patent Issue Date Used in PTA Calculation Critical | 21 Sep, 2010 | US7799771 |
US patents provide insights into the exclusivity only within the United States, but Femtrace is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Femtrace's family patents as well as insights into ongoing legal events on those patents.
Femtrace's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Femtrace's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 02, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Femtrace Generics:
There are no approved generic versions for Femtrace as of now.
Alternative Brands for Femtrace
Femtrace which is used for treating vasomotor symptoms associated with menopause., has several other brand drugs in the same treatment category and using the same active ingredient (Estradiol Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Aspen |
| |||
| Sebela Ireland Ltd |
| |||
| Wyeth Pharms |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Estradiol Acetate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Millicent |
|
About Femtrace
Femtrace is a drug owned by Allergan Pharmaceuticals International Ltd. It is used for treating vasomotor symptoms associated with menopause. Femtrace uses Estradiol Acetate as an active ingredient. Femtrace was launched by Apil in 2004.
Approval Date:
Femtrace was approved by FDA for market use on 20 August, 2004.
Active Ingredient:
Femtrace uses Estradiol Acetate as the active ingredient. Check out other Drugs and Companies using Estradiol Acetate ingredient
Treatment:
Femtrace is used for treating vasomotor symptoms associated with menopause.
Dosage:
Femtrace is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.9MG | TABLET | Discontinued | ORAL |
| 0.45MG | TABLET | Discontinued | ORAL |
| 1.8MG | TABLET | Discontinued | ORAL |